Lisata Therapeutics (LSTA) files Delaware suit against Kuva Labs, cuts 72% of staff after merger termination
The collapse of Lisata Therapeutics' planned combination with Kuva Labs has moved into the courts. Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) filed suit in the Delaware Court of Chancery on Tuesday, alleging that Kuva Labs and its subsidiary Kuva Acquisition Corp breached the merger agreement dated March 6, 2026. In focus for the tape: the $2 million termination fee Lisata says it is owed, and whether the board's ongoing strategic review produces a definitive agreement.
Key takeaways
- Lisata Therapeutics filed suit in the Delaware Court of Chancery on Tuesday alleging that Kuva Labs and its subsidiary Kuva Acquisition Corp breached their March 6, 2026 merger agreement.
- Lisata is seeking damages for stockholders and a $2 million termination fee it says the contract entitles it to collect.
- Lisata cut approximately 72% of its full-time positions, including the executive vice president of research and development and chief medical officer role.
- With the merger terminated, Lisata's board is evaluating strategic alternatives including acquisition, merger, reverse merger, other business combination, asset sales, and liquidation and dissolution.
- Lisata's lead asset is certepetide, an investigational cyclic peptide built on its CendR Platform designed to help anti-cancer drugs penetrate solid tumors more effectively.
The collapse of Lisata Therapeutics' planned combination with Kuva Labs has moved into the courts. Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) filed suit in the Delaware Court of Chancery on Tuesday, alleging that Kuva Labs and its subsidiary Kuva Acquisition Corp breached the merger agreement dated March 6, 2026. In focus for the tape: the $2 million termination fee Lisata says it is owed, and whether the board's ongoing strategic review produces a definitive agreement.
The lawsuit and the $2 million claim
The filing centers on the March 6, 2026 merger agreement. Lisata alleges breach and is pursuing two forms of relief: damages for the benefit of stockholders and the $2 million termination fee the company says the contract entitles it to collect. The Delaware Court of Chancery is the forum Lisata chose to press both claims, a standard venue for corporate disputes of this kind.
With the deal gone, the board said it is actively evaluating strategic alternatives. Those options span a potential acquisition, merger, reverse merger, other business combination, asset sales, and liquidation and dissolution. The company said it will provide an update once the board approves a definitive course of action or another disclosure becomes required.
Workforce reduction and the cash runway
Alongside the litigation, Lisata moved to cut costs sharply. The company reduced full-time positions by approximately 72%, including the executive vice president of research and development and chief medical officer role. Some affected employees may continue in a consulting capacity.
For a clinical-stage company, that scale of headcount reduction directly reshapes the cash runway available to fund the strategic review. The termination fee claim, if successful, would add $2 million to that position.
The pipeline: certepetide and what to watch
Lisata's lead asset is certepetide, an investigational cyclic peptide built on the company's CendR Platform. The therapy is designed to help co-administered or tethered anti-cancer drugs penetrate solid tumors more effectively. With the CMO role now vacant and the workforce reduced, certepetide's near-term path runs directly through whatever strategic direction the board settles on.
The next concrete marker for the tape is board approval of a definitive strategic decision, which Lisata said it will disclose once reached.
Filed by the newsroom of MarketPR on August 6, 2026. Source: finance.yahoo.com. Indicative figures are not investment advice.